It's early. It's early. We're definitely excited finally to bring IMAAVY to the marketplace, nipocalimab. It's the first and only FcRn blocker for a broad population of both pediatric as well as ...

JNJ’s Nipocalimab Development J&J is evaluating nipocalimab across multiple immunology and neuroscience indications in separate mid to late-stage clinical studies. Management is evaluating the ...

We are launching IMAAVY, nipocalimab in myasthenia gravis. We are launching our drug device combination Taris which is going to be branded in Lexo in localized bladder cancer. We are going to have ...

Moreover, J&J believes 10 of its new Innovative Medicine products, including new cancer drugs like Talvey and Tecvayli and pipeline candidates like nipocalimab and icotrokinra (JNJ-2113), have the ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

Investors in Johnson & Johnson (Symbol: JNJ) saw new options become available today, for the July 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the JNJ ...

Johnson & Johnson JNJ announced positive top-line data from a late-stage study evaluating the combination of niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, plus ...

View our complete analysis and fair value estimate and you decide. NYSE:JNJ Revenue & Expenses Breakdown as at Jun 2025 The end of cancer? These 23 emerging AI stocks are developing tech that will ...

Alert FDA Approves First One-Time Treatment for RDEB Wounds In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, compared ...

Analysts' ratings for Johnson & Johnson JNJ over the last quarter vary from bullish to bearish, as provided by 12 analysts. The following table encapsulates their recent ratings, offering a ...